Last reviewed · How we verify
Autologous mononuclear cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous mononuclear cells (Autologous mononuclear cells) — Timothy J Nelson, MD, PhD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous mononuclear cells TARGET | Autologous mononuclear cells | Timothy J Nelson, MD, PhD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous mononuclear cells CI watch — RSS
- Autologous mononuclear cells CI watch — Atom
- Autologous mononuclear cells CI watch — JSON
- Autologous mononuclear cells alone — RSS
Cite this brief
Drug Landscape (2026). Autologous mononuclear cells — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-mononuclear-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab